Lin Patrick 4

4 · Processa Pharmaceuticals, Inc. · Filed Aug 2, 2024

Form 4

Period: 2024-04-05

Chief Business - Strategy Off

Transactions

Tax Payment
Common Stock
2024-04-05$2.79/sh−539$1,504→ 28,686 total
Tax Payment
Common Stock
2024-07-10$1.71/sh−271$463→ 29,059 total
Award
Restricted Stock Units
2024-06-28+339→ 24,914 total
Exercise: $0.00→ Common Stock (339 underlying)
Award
Restricted Stock Units
2024-06-28+339→ 24,575 total
Exercise: $0.00→ Common Stock (339 underlying)
Exercise/Conversion
Common Stock
2024-04-05+1,675→ 29,225 total
Exercise/Conversion
Common Stock
2024-07-10+644→ 29,330 total
Award
Restricted Stock Units
2024-06-28+2,713→ 22,201 total
Exercise: $0.00→ Common Stock (2,713 underlying)
Award
Restricted Stock Units
2024-06-28+2,035→ 24,236 total
Exercise: $0.00→ Common Stock (2,035 underlying)

Footnotes (4)

[F1]Distribution of vested restricted shares.
[F2]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.
[F3]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.
[F4]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

Documents

1 file